leadf
logo-loader
NASDAQ:ORGS

Orgenesis

Receive alerts
Market:
NASDAQ
Market Cap:
$121.46 m
Price
4.95 USD
Change
-1.00%
52 weeks high
8.30
52 weeks low
4.15

In brief

Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.

Snapshot

The Maryland-based company is focused on unlocking the potential of personalized therapies and closed processing systems through its cell and gene therapy platform

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Biopharmaceuticals battling COVID-19 pandemic to connect with investors via Proactive One2One Investor Forum on September 10

Shareholders and others will have the opportunity to engage with CEOs from AIM ImmunoTech, Heat Biologics, Avalon GloboCare, Oregenisis, and ImmunoPrecise Antibodies

on 9/9/20